Advertisement

Search Results

Advertisement



Your search for all items matches 35084 pages

Showing 1 - 50


prostate cancer
bladder cancer
kidney cancer

Genitourinary Oncology Highlights: Treatment Advances in Renal Cell, Bladder, Urothelial, and Prostate Cancers

The 2025 ASCO Annual Meeting has officially concluded. Our sincere thanks to the global oncology community and ASCO for creating such a remarkable forum advancing cancer care. Here we highlight the most impactful updates in genitourinary tumors from this year’s meeting. Kidney Cancer: Long-Term...

leukemia

Frontline Triplet Regimens for Intensive Chemotherapy-Ineligible IDH-Mutant AML

In a single-center study reported in the Journal of Clinical Oncology, DiNardo et al investigated whether frontline triplet regimens consisting of a hypomethylating agent, venetoclax, and an isocitrate dehydrogenase inhibitor were active in intensive chemotherapy-ineligible patients with IDH-mutant ...

breast cancer

Partial-Breast Radiotherapy After Breast-Conserving Surgery: 10-Year Outcomes

As reported in The Lancet Oncology by Kirby et al, 10-year follow-up of the phase III UK IMPORT LOW trial has shown that partial-breast and reduced-dose radiotherapy continue to be associated with similar ipsilateral breast tumor recurrence (IBTR) outcomes compared with whole-breast radiotherapy...

issues in oncology
global cancer care

Study Finds About One in Six Chemotherapy Drugs in Sub-Saharan Africa Fails Quality Tests

About one in six tested chemotherapies in sub-Saharan Africa were found to have serious quality defects, according to the results of a study published in The Lancet Global Health.   Researchers assessed the appearance, packaging, and labeling of each cancer medication and measured the quantity of...

cns cancers

ASTRO Updates Guideline on Radiation Therapy for High-Grade Diffuse Glioma

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) focuses on the use of radiation therapy for adults with World Health Organization (WHO) grade 4 diffuse gliomas, a category that includes some of the most common and most aggressive primary brain tumors. The...

colorectal cancer

Addition of Retifanlimab to First-Line Chemotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal

In a phase III trial (POD1UM-303/InterAACT-2) reported in The Lancet, Rao et al investigated the survival benefit of adding the PD-1 inhibitor retifanlimab to carboplatin-paclitaxel in patients with locally recurrent or metastatic squamous cell carcinoma of the anal canal. Study Details In the...

prostate cancer
symptom management

Botulinum Toxin and Scopolamine for Radiation-Induced Salivary Gland Toxicity in Metastatic Prostate Cancer

Injection with botulinum toxin (BTX) type A (IncoA) plus transdermal scopolamine led to the reduction in radiation-induced salivary gland toxicity without compromising PSMA (prostate-specific membrane antigen) tumor uptake in patients with metastatic prostate cancer who were receiving...

colorectal cancer
immunotherapy

Predictive Biomarker Under Study in Colorectal Cancer

Researchers have uncovered a biomarker that may determine response to cytokine-induced killer-cell therapy and survival in patients with colorectal cancer, according to a recent study published by Li et al in The Journal of Immunology. Background Colorectal cancer is the second-leading cause of...

solid tumors
genomics/genetics

Best Practice Recommendations for Clinical Homologous Recombination Deficiency Testing

The Association for Molecular Pathology has introduced best practice recommendations for clinical laboratories developing and performing homologous recombination deficiency testing, according to new guidelines published by Hsiao et al in The Journal of Molecular Diagnostics. Background Homologous...

prostate cancer

Early Toxicity With Moderately Hypofractionated vs Stereotactic Body Radiotherapy in Prostate Cancer

In an analysis from a phase III trial (PACE-C) reported in The Lancet Oncology, Tree et al compared early toxicity rates with intensity-modulated moderately hypofractionated radiotherapy (MHRT) vs stereotactic body radiotherapy (SBRT) in patients with intermediate- and high-risk prostate...

head and neck cancer

Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer

In an interim analysis of a phase III trial (KEYNOTE-689) reported in The New England Journal of Medicine, Uppaluri et al examined the survival benefit of adding perioperative pembrolizumab to standard care in patients with locally advanced head and neck squamous cell carcinoma. Study Details In...

breast cancer
survivorship

Breast Cancer: New Study Finds Survivors May Face Lower Risk of Alzheimer Dementia

Breast cancer survivors may have a slightly lower risk of developing Alzheimer dementia compared with cancer-free individuals, according to the results of a study published by Jeong et al in JAMA Network Open. “The risk of Alzheimer dementia is a crucial aspect of overall well-being among breast...

gastrointestinal cancer
neuroendocrine tumors
pancreatic cancer

Case 3: Radioligands in Advanced Neuroendocrine Tumor

This is Part 3 of Evolving Treatment Paradigms for Neuroendocrine Tumors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Daniel Halperin, Jess Maxwell, and Virginia Corbett discuss the use of radioligand therapy for advanced...

neuroendocrine tumors
gastrointestinal cancer

Case 2: Well-Differentiated Grade 3 Small Bowel Neuroendocrine Tumor

This is Part 2 of Evolving Treatment Paradigms for Neuroendocrine Tumors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Daniel Halperin, Jess Maxwell, and Virginia Corbett discuss the treatment of well-differentiated grade 3...

gastrointestinal cancer
neuroendocrine tumors
pancreatic cancer

Case 1: Pancreatic Neuroendocrine Tumor

This is Part 1 of Evolving Treatment Paradigms for Neuroendocrine Tumors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Daniel Halperin, Jess Maxwell, and Virginia Corbett discuss the treatment pancreatic neuroendocrine...

leukemia

Dual Menin and KAT6A/7 Inhibition Improves Outcomes in NUP98-Rearranged Pediatric AML Models

A combination of menin inhibition and KAT6A/7 inhibition significantly improved survival for NUP98-rearranged pediatric acute myeloid leukemia (AML) in AML model systems, even in menin inhibitor–resistant cells, according to findings published in Cancer Discovery. The MYST gene family histone...

issues in oncology

Study Finds AI Chatbots Are Vulnerable to Spreading Malicious, False Health Information

While artificial intelligence (AI) large language models (LLMs) hold the promise to help consumers find trustworthy health information, a study assessing the safeguards incorporated into these models has found that they are vulnerable to malicious instruction that converts them into health...

issues in oncology

Nearly 50% of All Cancer Deaths Worldwide Attributable to Modifiable Risk Factors

New data reported in The Cancer Atlas, Fourth Edition showed that an estimated 50% of all cancer deaths worldwide are attributed to modifiable risk factors, including tobacco and alcohol use, infections, excess body weight, unhealthy diet, physical inactivity, ultraviolet radiation exposure,...

hepatobiliary cancer

GPC3-Targeted ImmunoPET Helps Detect Earlier-Stage Hepatocellular Carcinoma

A novel immuno–positron-emission tomography (immunoPET) imaging agent targeting GPC3 demonstrated high sensitivity and specificity in detecting GPC3-positive hepatocellular carcinoma (HCC) tumors, including those under 1 cm, according to the results of a pilot clinical study presented at the...

hematologic malignancies

Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera

In patients with polycythemia vera requiring frequent phlebotomies, the investigational hepcidin mimetic rusfertide, given as a weekly subcutaneous injection, more than doubled the clinical response rate and significantly improved quality of life in the global phase III VERIFY study.1 These...

gynecologic cancers

Mailed Self-Collection HPV Tests Improve Cervical Cancer Screening Rates, Study Finds

Mail-in self-collection tests for human papillomavirus (HPV) more than doubled cervical cancer screening participation among never- and under-screened U.S. women, according to a first-of-its-kind study from researchers at The University of Texas MD Anderson Cancer Center. In the real-world,...

The Ohio State Appoints Christian Rolfo, MD, PhD, MBA, to Lead Division of Medical Oncology

Christian Rolfo, MD, PhD, MBA, has been appointed Director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James). He will assume this position on August 15. Dr. Rolfo will ...

lung cancer

I Was Expecting to Hear I Have Heart Disease, Not Cancer

In 2022, I had a computed tomography (CT) coronary calcium scan to see whether there were any signs of narrowing or blockage in my heart arteries. Heart disease runs in my family. My father died of a heart attack the year before, and I worried that I was at risk for the same fate. It was a complete ...

W. Kimryn Rathmell, MD, PhD, FASCO, Selected for Women Who Conquer Cancer Mentorship Award

W. Kimryn Rathmell, MD, PhD, FASCO, has been selected for the prestigious 2025 Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. Launched in 2016, the Women Who Conquer Cancer award program honors extraordinary women leaders in oncology and role models who have excelled as mentors...

William C. Wood, MD, FASCO, Renowned Surgeon, Esteemed Mentor, Global Academic Dean, Dies at 84

William C. “Bill” Wood, MD, FASCO, a leader and mentor in the field of breast cancer, died on August 18, 2024. He was 84. Dr. Wood was the J.B. Whitehead Professor and Chair of the Department of Surgery at Emory University School of Medicine from 1991 to 2009. He chaired the 1990 U.S. National...

Malignant Hematology Expert and Medicare Reimbursement Advocate, Samuel M. Silver, MD, PhD, FRCP, FASCO, MACP, Dies at 74

The ASCO Post would like to pay tribute to Samuel M. Silver, MD,PhD, FRCP, FASCO, MACP, who died on August 14, 2024, at the age of 74. Dr. Silver was renowned in the hematology and oncology community and a respected member of the editorial advisory board of The ASCO Post. Additionally, he served...

Minnesota Society of Clinical Oncology Recognized for Advocacy at 2025 ASCO Annual Meeting

The Minnesota Society of Clinical Oncology (MSCO) is the recipient of the 2024 Jeffery C. Ward Affiliate Advocacy Award. The Association for Clinical Oncology presented the award during the State Affiliates’ Reception at the 2025 ASCO Annual Meeting. Presented annually, the Jeffery C. Ward...

Number of Cancer Survivors in the United States Reaches 18.6 Million and Projected to Exceed 22 Million by 2035

The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025, and projected to exceed 22 million by 2035, according to a new report, Cancer Treatment and Survivorship Statistics, 2025, led by the American Cancer Society (ACS). The...

colorectal cancer

Chinese Herbal Medicine for Improving Adjuvant Chemotherapy Completion in Patients With Colon Cancer

Guest Editor’s Note: Although guidelines recommend adjuvant combination chemotherapy for patients with stage II and III colon cancer who are at high risk of disease recurrence, fewer than 50% complete treatment because of fear of adverse effects or symptom burden. The herbal formula Jianpi Bushen ...

breast cancer

Preoperative Endocrine Therapy for Older Women With Estrogen Receptor–Positive Breast Cancer: Impact on Radiotherapy Decisions

Providing a brief, 90-day course of preoperative endocrine therapy to older women with early-stage, estrogen receptor–positive, invasive breast cancer may significantly alter both patient preferences and physician recommendations regarding adjuvant radiation therapy, according to data presented...

hematologic malignancies

HLA-Matching Considerations for Hematopoietic Cell Transplantation in Hematologic Malignancies

Besides relapse of the malignant disease, graft-vs-host disease is still one of the greatest concerns, in terms of adverse effects, following a hematopoietic cell transplantation (HCT) in a patient with a hematologic malignancy. To mitigate these concerns, investigators are continually analyzing ...

ASCO Honors Karen Eubanks Jackson of Sisters Network® Inc. With 2025 Patient Advocate Award

Karen Eubanks Jackson, founder and Chief Executive Officer of Sisters Network® Inc. (SNI), has been named the recipient of the 2025 Patient Advocate Award by ASCO, Conquer Cancer, and the ASCO Foundation. The awards ceremony was held during the 2025 ASCO Annual Meeting. (See a video with Ms....

breast cancer

Vepdegestrant vs Fulvestrant in Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer

Based on the findings of the VERITAC-2 trial, treatment with the selective PROTAC (proteolysis targeting chimera) estrogen receptor degrader vepdegestrant yielded statistically significant and clinically meaningful improvement in progression-free survival in patients with ESR1-mutant, estrogen...

issues in oncology

ASCO and Medicaid: Advocacy In Action

The Association for Clinical Oncology (ASCO) is actively engaged in advocacy to protect Medicaid access for millions of Americans. Members can support ASCO’s Medicaid advocacy efforts through the ACT Network. In 2025, ASCO has partnered with other health-care organizations and engaged with...

National Comprehensive Cancer Network Launches NCCN Guidelines Navigator

The National Comprehensive Cancer Network® (NCCN®) has announced a new, interactive digital delivery format for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The NCCN Guidelines® are the recognized standard for clinical decision-making and policy in cancer care and are the...

breast cancer

ASCO Guideline Update Calls for Omission of SLNB in Select Patients With Early-Stage Breast Cancer

ASCO has released a clinical practice guideline update on the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer.1 The update includes recommendations based on findings from trials released after the published guideline in 2017, including data from nine randomized trials...

gastroesophageal cancer

In Second-Line Setting, T-DXd Improves Survival Outcomes in HER2-Positive Gastric or Gastroesophageal Junction Cancer

In the phase III DESTINY-Gastric04 trial, use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was compared head to head with the monoclonal antibody ramucirumab and paclitaxel in patients with previously treated, HER2-positive metastatic gastric or gastroesophageal junction...

issues in oncology

ACS Study Focuses on Effects of Medicaid Expansion in Low-Income Older Adults With Cancer

A recent study by researchers at the American Cancer Society (ACS) showed that Medicaid expansion was associated with an increase in Medicaid coverage, early-stage cancer diagnoses, and improved 2-year survival among individuals aged 65 or older who were diagnosed with cancer. They believe these...

colorectal cancer

Updated Results Confirm Benefit of Combination Regimen in BRAFV600E–Mutated Metastatic Colorectal Cancer

Patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer who receive the BRAF inhibitor encorafenib and the EGFR inhibitor cetuximab plus mFOLFOX6 (modified leucovorin, fluorouracil, and oxaliplatin) vs the current standard of care (chemotherapy ± bevacizumab) may live...

Case 3: Second-Line Treatment of ER-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 and PIK3CA Mutations

This is Part 3 of The Role of Oral SERDs in Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Komal Jhaveri, Erika Hamilton, and Aditya Bardia discuss the treatment of a 64-year-old postmenopausal woman...

Case 2: Second-Line Treatment of ER-Positive, HER2-Negative Metastatic Breast Cancer and ESR1 D538G Mutation After Progression on CDK4/6 Inhibitor

This is Part 2 of The Role of Oral SERDs in Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Komal Jhaveri, Erika Hamilton, and Aditya Bardia discuss the treatment of a 67-year-old postmenopausal woman...

breast cancer

Case 1: First-Line Treatment of HR-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 Y537S Mutation

This is Part 1 of The Role of Oral SERDs in Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Komal Jhaveri, Erika Hamilton, and Aditya Bardia discuss the treatment of a 61-year-old female patient who...

prostate cancer

FDA Approves Label Expansion for Agent Used in Patient Selection for Pre-Taxane Radioligand Therapy

The U.S. Food and Drug Administration (FDA) has approved a label expansion of a kit for the preparation of gallium Ga-68 gozetotide for injection (Illuccix) to include patient selection for radioligand therapy in the pre-taxane setting. The update applies to the imaging agent’s third indication,...

breast cancer

Early ESR1 Mutation Detection and Therapy Switch in Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer

Early detection of an ESR1 mutation, leading to a switch of endocrine therapy, led to an almost doubling in progression-free survival in the SERENA-6 trial, the global registrational study in patients with metastatic breast cancer for the investigational oral selective estrogen receptor degrader...

issues in oncology

Silence Is Complicity

On January 20, 2025, newly sworn-in President Donald J. Trump signed Executive Order 14151, “Ending Radical and Wasteful Government DEI Programs and Preferencing,”1 effectively eliminating all diversity, equity, and inclusion (DEI) programs, preferences, and activities across the federal...

colorectal cancer

Adjuvant Use of Atezolizumab Plus Chemotherapy in DNA Mismatch Repair–Deficient Colon Cancer

For the adjuvant treatment of stage III colon cancer with DNA mismatch repair–deficient (dMMR) tumors, the addition of the checkpoint inhibitor atezolizumab to standard chemotherapy significantly improved disease-free survival in the phase III ATOMIC trial. The results position this approach as a...

breast cancer

Phase III Trial Results Suggest a New Standard of Care in Metastatic HER2-Positive Breast Cancer

In the phase III DESTINY-Breast09 trial, first-line treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) plus the monoclonal antibody pertuzumab significantly delayed disease progression by more than 1 year—nearly doubling the time of disease control—over standard...

skin cancer

Role of Mitochondrial Pathways in Melanoma Progression, Treatment Resistance

The most aggressive melanomas may hyperactivate two key processes in mitochondria, according to a novel study, and blocking these pathways with currently available drugs may eliminate melanoma cells, explained investigators. These findings were published by Kim et al in the journal Cancer....

gastroesophageal cancer

Addition of Lenvatinib/Pembrolizumab to Chemotherapy in Advanced/Metastatic Gastroesophageal Adenocarcinoma

In an interim analysis of the phase III LEAP-015 trial reported in the Journal of Clinical Oncology, Shitara et al examined the survival benefit of adding lenvatinib-pembrolizumab to chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma. Study Details In the open-label...

breast cancer

Adding Olanzapine to Triplet Antiemetics Post–Anthracycline/Cyclophosphamide Chemotherapy

In a phase III Japanese trial reported in The Lancet Oncology, Saito et al examined the efficacy of adding 5 mg of olanzapine to triplet antiemetic therapy in controlling chemotherapy-induced nausea and vomiting in the overall phase when given after receipt of anthracycline-cyclophosphamide...

Advertisement

Advertisement




Advertisement